BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01603615|
Recruitment Status : Completed
First Posted : May 22, 2012
Results First Posted : August 21, 2019
Last Update Posted : August 21, 2019
|Condition or disease||Intervention/treatment||Phase|
|Pediatrics Muscle Spasticity Cerebral Palsy Stroke||Biological: Botulinum Toxin Type A||Phase 3|
|Study Type :||Interventional|
|Actual Enrollment :||220 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||BOTOX® Treatment in Pediatric Upper Limb Spasticity: Open-label Study|
|Actual Study Start Date :||October 30, 2012|
|Actual Primary Completion Date :||September 3, 2018|
|Actual Study Completion Date :||September 3, 2018|
Participants received a maximum of 5 treatments of intramuscular injections of BOTOX® (botulinum toxin Type A) into upper limb and/or lower limb muscles at a minimum of 12 weeks apart. Treatment dosing was according to investigator judgment, de novo participants received at least 6 U/kg of body weight or a maximum of 8 U/kg of body weight (not to exceed 300 U). Rollover participants received up to a maximum of 8 U/kg of body weight (not to exceed 300 U) for treatment Cycle 1. Dose could be increased to a maximum of 10 U/kg (not to exceed 340 U) in treatment Cycles 2-5. Rolled over participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 3 or 6 U/kg into upper limb in previous study or were de novo participants who were not enrolled in previous study.
Biological: Botulinum Toxin Type A
Participants received intramuscular injections of botulinum Toxin Type A in the upper and/or lower limb muscles at a minimum of 12 weeks apart for a maximum of 5 treatments.
Other Name: BOTOX® OnabotulinumtoxinA
- Percentage of Participants With at Least One Treatment- Emergent Adverse Event (TEAE) [ Time Frame: From first dose of study drug up to 12 weeks post last dose (Up to 60 weeks) ]An adverse event (AE) was any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. A TEAE was an AE that occurred after receiving the first dose of investigational product or an AE present prior to first dose but increased in severity during the Treatment Period. Safety population included all treated participants.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01603615
|Study Director:||Emily McCusker||Allergan|